

**Table 1. Subject characteristics**

	Japan		U.S.	
	<sup>a</sup> Incidence (n=33,688)	Mortality (n=74,972)	<sup>b</sup> Incidence (n=37,121)	Mortality (n=229,290)
Age (%)				
0-49	1,191 (3.54)	1,232 (1.64)	2,829 (7.62)	7,541 (3.29)
50-59	3,426 (10.17)	5,151 (6.87)	6,138 (16.54)	23,703 (10.34)
60-69	8,207 (24.36)	15,211 (20.29)	9,389 (25.29)	49,366 (21.53)
70-79	11,667 (34.63)	26,459 (35.29)	10,686 (28.79)	75,325 (32.85)
80+	9,197 (27.30)	26,919 (35.91)	8,079 (21.76)	73,355 (31.99)
Sex (%)				
Male	17,256 (51.22)	37,643 (50.21)	20,395 (54.94)	120,753 (52.66)
Female	16,432 (48.78)	37,329 (49.79)	16,726 (45.06)	108,537 (47.34)

<sup>a</sup>Incidence data in Japan were obtained from 13 registries (Miyagi, Yamagata, Chiba, Kanagawa, Niigata, Fukui, Aichi, Shiga, Osaka, Tottori, Yamaguchi, Nagasaki, and Kumamoto).

<sup>b</sup>Incidence data in the U.S. were obtained from nine registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah).

**Table 2. Trends in age-specific mortality and incidence rate**

		AAPC (95%CI)			Trend 1			Trend 2			Trend 3					
					Period	APC (95%CI)		Period	APC (95%CI)		Period	APC (95%CI)				
Japan	Total															
	Mortality	<b>-1.5</b>	<b>(-1.7</b>	<b>- -1.2)</b>	1995-2005	-0.4	(-0.8	- 0.0)	2005-2015	<b>-2.5</b>	<b>(-2.9</b>	<b>- -2.1)</b>				
	Incidence	<b>0.9</b>	<b>(0.6</b>	<b>- 1.2)</b>	1995-2015	<b>0.9</b>	<b>(0.6</b>	<b>- 1.2)</b>								
	Male															
	Mortality	<b>-1.5</b>	<b>(-1.9</b>	<b>- -1.1)</b>	1995-2004	-0.4	(-1.2	- 0.3)	2004-2015	<b>-2.3</b>	<b>(-2.8</b>	<b>- -1.8)</b>				
	Incidence	<b>0.8</b>	<b>(0.5</b>	<b>- 1.1)</b>	1995-2015	<b>0.8</b>	<b>(0.5</b>	<b>- 1.1)</b>								
U.S.	Female															
	Mortality	<b>-1.5</b>	<b>(-1.9</b>	<b>- -1.1)</b>	1995-2005	-0.2	(-0.9	- 0.4)	2005-2015	<b>-2.7</b>	<b>(-3.4</b>	<b>- -2.1)</b>				
	Incidence	<b>0.9</b>	<b>(0.4</b>	<b>- 1.3)</b>	1995-2015	<b>0.9</b>	<b>(0.4</b>	<b>- 1.3)</b>								
	Total															
	Mortality	<b>-1.1</b>	<b>(-1.4</b>	<b>- -0.9)</b>	1995-2002	<b>-0.9</b>	<b>(-1.4</b>	<b>- -0.5)</b>	2002-2009	<b>-2.0</b>	<b>(-2.6</b>	<b>- -1.5)</b>	2009-2015	-0.3	(-0.8	- 0.3)
	Incidence	0.9	(-0.3	- 2.0)	1995-2007	0.4	(-0.1	- 0.9)	2007-2010	3.9	(-3.6	- 12.0)	2010-2015	0.1	(-1.4	- 1.6)
U.S.	Male															
	Mortality	<b>-1.2</b>	<b>(-1.3</b>	<b>- -1.1)</b>	1995-2015	<b>-1.2</b>	<b>(-1.3</b>	<b>- -1.1)</b>								
	Incidence	<b>1.1</b>	<b>(0.9</b>	<b>- 1.4)</b>	1995-2015	<b>1.1</b>	<b>(0.9</b>	<b>- 1.4)</b>								
	Female															
	Mortality	<b>-1.4</b>	<b>(-1.8</b>	<b>- -0.9)</b>	1995-2002	<b>-1.0</b>	<b>(-1.7</b>	<b>- -0.3)</b>	2002-2008	<b>-2.9</b>	<b>(-4.0</b>	<b>- -1.7)</b>	2008-2015	-0.4	(-1.1	- 0.3)
	Incidence	<b>0.9</b>	<b>(0.5</b>	<b>- 1.2)</b>	1995-2015	<b>0.9</b>	<b>(0.5</b>	<b>- 1.2)</b>								

Values significantly different from zero (two-sided P<0.05, calculated using a t-test) are highlighted in bold.

Japan: phase I/II study of the first novel agent was started in May 2004, and approval of the first novel agent was received in October 2006.

U.S.: phase I/II study of the first novel agent was started in December 1997, and approval of the first novel agent was received in May 2003.

Abbreviations: APC, annual percent change; CI, confidence interval; AAPC, average annual percent change

**Table 3. Trends in age-categorized mortality and incidence rate**

	AAPC (95%CI)	Trend 1		Trend 2		Trend 3	
		Period	APC (95%CI)	Period	APC (95%CI)	Period	APC (95%CI)
<b>Japan</b>							
0-49							
Mortality	-1.3 (-4.0 - 1.6)	1995-1997	11.6 (-13.1 - 43.4)	1997-2007	<b>-5.8 (-8.2 - -3.4)</b>	2007-2015	1.6 (-2.0 - 5.3)
Incidence	<b>2.5 (1.5 - 3.5)</b>	1995-2015	<b>2.5 (1.5 - 3.5)</b>				
50-59							
Mortality	<b>-2.6 (-3.5 - -1.6)</b>	1995-2008	<b>-1.0 (-1.9 - -0.2)</b>	2008-2015	<b>-5.3 (-7.8 - -2.8)</b>		
Incidence	<b>1.7 (1.1 - 2.2)</b>	1995-2015	<b>1.7 (1.1 - 2.2)</b>				
60-69							
Mortality	<b>-2.3 (-2.6 - -2.0)</b>	1995-2015	<b>-2.3 (-2.6 - -2.0)</b>				
Incidence	<b>0.8 (0.3 - 1.3)</b>	1995-2015	<b>0.8 (0.3 - 1.3)</b>				
70-79							
Mortality	<b>-1.2 (-1.6 - -0.8)</b>	1995-2004	<b>1.2 (0.4 - 2.0)</b>	2004-2015	<b>-3.1 (-3.7 - -2.6)</b>		
Incidence	<b>0.7 (0.3 - 1.1)</b>	1995-2015	<b>0.7 (0.3 - 1.1)</b>				
80+							
Mortality	0.0 (-0.2- - 0.3)	1995-2015	0.0 (-0.2- - 0.3)				
Incidence	<b>0.6 (0.2 - 1.0)</b>	1995-2015	<b>0.6 (0.2 - 1.0)</b>				
<b>U.S.</b>							
0-49							
Mortality	<b>-2.3 (-2.8 - -1.8)</b>	1995-2015	<b>-2.3 (-2.8 - -1.8)</b>				
Incidence	<b>2.3 (1.7 - 2.9)</b>	1995-2015	<b>2.3 (1.7 - 2.9)</b>				
50-59							
Mortality	<b>-2.3 (-2.5 - -2.1)</b>	1995-2015	<b>-2.3 (-2.5 - -2.1)</b>				
Incidence	1.0 (0.0 - 2.1)	1995-2007	-0.3 (-1.6 - 1.0)	2007-2015	<b>3.0 (1.0 - 5.1)</b>		
60-69							
Mortality	<b>-2.3 (-2.5 - -2.0)</b>	1995-2015	<b>-2.3 (-2.5 - -2.0)</b>				
Incidence	<b>0.7 (0.3 - 1.0)</b>	1995-2015	<b>0.7 (0.3 - 1.0)</b>				
70-79							
Mortality	<b>-0.8 (-1.3 - -0.4)</b>	1995-2002	0.1 (-0.5 - 0.8)	2002-2008	<b>-2.1 (-3.1 - -1.0)</b>	2008-2015	<b>-0.7 (-1.4 - 0.0)</b>
Incidence	<b>1.0 (0.7 - 1.4)</b>	1995-2015	<b>1.0 (0.7 - 1.4)</b>				
80+							
Mortality	0.5 (0.0 - 0.9)	1995-2002	0.5 (-0.3 - 1.3)	2002-2008	-0.9 (-2.2 - 0.3)	2008-2015	<b>1.6 (0.9 - 2.3)</b>
Incidence	<b>0.7 (0.2 - 1.2)</b>	1995-2015	<b>0.7 (0.2 - 1.2)</b>				

Values significantly different from zero (two-sided P<0.05, calculated using a t-test) are highlighted in bold.

Japan: phase I/II study of the first novel agent was started in May 2004, and approval of the first novel agent was received in October 2006.

U.S.: phase I/II study of the first novel agent was started in December 1997, and approval of the first novel agent was received in May 2003.

Abbreviations: APC, annual percent change; CI, confidence interval; AAPC, average annual percent change